US13471N3008 - ADR
2.24 -0.09 (-3.86%)
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!
OncoSec Medical (ONCS) +65%. GlucoTrack (GCTK) +29%
Can-Fite BioPharma (CANF) has entered agreements for the purchase and sale of 1M ADSs at a purchase price of $5.50 per ADS, in a registered direct offering
Can-Fite BioPharma (CANF) said it will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing 30 ordinary shares to a new ratio of one...
Can-Fite BioPharma (CANF) gained pre-market Wednesday on latest findings on its liver cancer therapy Namodenoson ahead of two investor events. Read the full story here.
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.